Only MLH1 and MSH2 carriers developed CRCs during surveillance, whereas MSH6, PMS2, EPCAM carriers and patients with a mixed genotype did not develop CRC during surveillance (p=0.01). Here, PMS2 is linked to colorectal carcinoma.